Summary
The excretion of cyclophosphamide and the enzymatically derived metabolites 4-ketocyclophosphamide and carboxyphosphamide has been measured in four patients after the administration of cyclophosphamide (5 g). At this dose the enzymes responsible for the biotransformation and detoxification of cyclophosphamide are not saturated. In two patients the metabolite profile was unaffected by a previous high dose of cyclophosphamide and in one patient a small primary dose did not alter metabolism.
This is a preview of subscription content, log in via an institution to check access.
References
Allen LM, Creaven PJ, Nelson RL (1976) Studies on the human pharmacokinetics of isophosphamide. Cancer Treat Rep 60: 451
Bagley CM Jr, Bostick FW, De Vita VT Jr (1973) Clinical pharmacology of cyclophosphamide. Cancer Res 33: 226
Cohen JL, Jao JY, Jusko WS (1971) Pharmacokinetics of cyclophosphamide in man. Br J Pharmacol 43: 677
Cox PJ, Farmer PB, Foster AB, Griggs LJ, Larman M, Kinas R, Pankiewicz K, Stec WJ (1977) Application of deuterium labelling mass spectrometry in a study of the metabolism of the enantiomers of cyclophosphamide. Biomed Mass Spectrometry 4: 371
Cox PJ, Phillips BJ, Thomas P (1975) The enzymatic basis for the selective action of cyclophosphamide. Cancer Res 35: 3755
Griggs LJ, Jarman M (1975) Synthesis of deuterium-labeled analogs of cyclophosphamide and its metabolites. J Med Chem 18: 1102
Jarman M, Milsted RAV, Smyth JF, Kinas RW, Pankiewicz K, Stec WJ (1979) Comparative metabolism of 2-bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide (cyclophosphamide) and its enantiomers in humans. Cancer Res 39: 2762
McElwain TJ, Hedley DW, Burton G, Clink HM, Gordon MY, Jarman M, Juttner CA, Millar JL, Milsted RVA, Prentice G, Smith IE, Spence D, Woods M (1979) Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high dose melphalan. Br J Cancer 40: 72
Millar JL, Hudspith BN, Blackkett NM (1975) Reduced lethality in mice receiving a combined dose of cyclophosphamide and busulphan. Br J Cancer 32: 193
Millar JL, McElwain TJ (1978) Combinations of cytotoxic agents that have less expected toxicity on normal tissues in mice. Antibiotics Chemother 23: 271
Mouridsen HT, Faber O, Skovsted L (1974) The biotransformation of cyclophosphamide in man. Analysis of the variation in normal subjects. Acta Pharmacol Toxicol 35: 98
Sladek N (1973) Evidence for an aldehyde possessing alkylating activity as the primary metabolite of cyclophosphamide. Cancer Res 33: 651
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Milsted, R.A.V., Jarman, M. Metabolism of high doses of cyclophosphamide. Cancer Chemother. Pharmacol. 8, 311–313 (1982). https://doi.org/10.1007/BF00254056
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254056